IDH2 and central nervous system neoplasm: Although considered rare in pediatrics, in a recent genomic study of 50 adolescents and young adults (AYAs) with HGGs and high-risk CNS tumors, 50% were found to be IDH-mutant, either diagnosed upfront or identified/reclassified by methylation analysis [50].